{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:04:23Z","timestamp":1783533863984,"version":"3.55.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2009,6,24]],"date-time":"2009-06-24T00:00:00Z","timestamp":1245801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently coexist. No study has prospectively examined the effects of beta-blockade in those with both conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We randomized 27 patients with HF and coexistent moderate or severe COPD to receive bisoprolol or placebo, titrated to maximum tolerated dose over 4 months. The primary outcome was forced expiratory volume in 1 s (FEV1). The study is registered with ClinicalTrials.gov, number: NCT00702156. Patients were elderly and predominantly male. Cardiovascular comorbidity, smoking history, and pulmonary function were similar in each group (mean FEV1 1.37 vs. 1.26 L, P = 0.52). A reduction in FEV1 occurred after 4 months following treatment with bisoprolol compared with placebo (\u221270 vs. +120 mL, P = 0.01). Reversibility following inhaled \u03b22-agonist and static lung volumes were not impaired by bisoprolol. All measures of health status exhibited a consistent non-significant improvement, including the Short Form 36 physical and mental component scores (2.6 vs. 0.5 and 0.8 vs. \u22120.3, respectively), Minnesota Living with Heart Failure Questionnaire (\u22122.5 vs. 3.5) and Chronic Respiratory Questionnaire (0.07 vs. \u22120.24). The mean number of COPD exacerbations was similar in the bisoprolol and placebo groups (0.50 and 0.31, respectively, P = 0.44).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Initiation of bisoprolol in patients with HF and concomitant moderate or severe COPD resulted in a reduction in FEV1. However, symptoms and quality of life were not impaired.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfp066","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T20:44:22Z","timestamp":1242938662000},"page":"684-690","source":"Crossref","is-referenced-by-count":86,"title":["Bisoprolol in Patients with Heart Failure and Moderate to Severe Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial"],"prefix":"10.1093","volume":"11","author":[{"given":"Nathaniel M.","family":"Hawkins","sequence":"first","affiliation":[{"name":"Aintree Cardiac Centre, University Hospital Aintree , Longmoor Lane, Liverpool, L9 7AL ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Royal Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"Royal Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Chalmers","sequence":"additional","affiliation":[{"name":"Royal Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Carter","sequence":"additional","affiliation":[{"name":"Royal Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis G.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Stobhill Hospital , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"Western Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,6,24]]},"reference":[{"key":"2026020203382742200_ejhfhfp066-bib-0001","author":"GOLD Global Initiative for Chronic Obstructive Lung Disease"},{"key":"2026020203382742200_ejhfhfp066-bib-0002","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"2026020203382742200_ejhfhfp066-bib-0003","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/eurjhf\/hfn013","article-title":"Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology","volume":"11","author":"Hawkins","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203382742200_ejhfhfp066-bib-0004","first-page":"e154","article-title":"ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"2026020203382742200_ejhfhfp066-bib-0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","article-title":"The EuroHeart Failure Survey programme\u2014a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment","volume":"24","author":"Komajda","year":"2003","journal-title":"Eur Heart J"},{"key":"2026020203382742200_ejhfhfp066-bib-0006","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0140-6736(64)92617-0","article-title":"Effect of a beta-adrenergic-blocking agent, propranolol, on asthmatics","volume":"13","author":"McNeill","year":"1964","journal-title":"Lancet"},{"key":"2026020203382742200_ejhfhfp066-bib-0007","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/bmj.282.6263.548","article-title":"Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane","volume":"282","author":"Raine","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2026020203382742200_ejhfhfp066-bib-0008","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM196609152751103","article-title":"Bronchial response to beta-adrenergic blockade","volume":"275","author":"Zaid","year":"1966","journal-title":"N Engl J Med"},{"key":"2026020203382742200_ejhfhfp066-bib-0009","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/thorax.58.6.515","article-title":"Health status measurement: sensitivity of the self-reported Chronic Respiratory Questionnaire (CRQ-SR) in pulmonary rehabilitation","volume":"58","author":"Williams","year":"2003","journal-title":"Thorax"},{"key":"2026020203382742200_ejhfhfp066-bib-0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2026020203382742200_ejhfhfp066-bib-0011","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur Respir J"},{"key":"2026020203382742200_ejhfhfp066-bib-0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society","volume":"16","author":"Quanjer","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"2026020203382742200_ejhfhfp066-bib-0013","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"2026020203382742200_ejhfhfp066-bib-0014","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"Br Med J"},{"key":"2026020203382742200_ejhfhfp066-bib-0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bmj.1.6157.168","article-title":"Comparison of effects of propranolol and metoprolol on airways obstruction in chronic bronchitis","volume":"1","author":"Sinclair","year":"1979","journal-title":"Br Med J"},{"key":"2026020203382742200_ejhfhfp066-bib-0016","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.78.5.714","article-title":"Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease. Effects and interaction after oral administration","volume":"78","author":"Wunderlich","year":"1980","journal-title":"Chest"},{"key":"2026020203382742200_ejhfhfp066-bib-0017","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/BF01856511","article-title":"Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease","volume":"4","author":"Fogari","year":"1990","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026020203382742200_ejhfhfp066-bib-0018","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.103.10.1428","article-title":"Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial","volume":"103","author":"Lechat","year":"2001","journal-title":"Circulation"},{"key":"2026020203382742200_ejhfhfp066-bib-0019","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0954-6111(03)00168-9","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis","volume":"97","author":"Salpeter","year":"2003","journal-title":"Respir Med"},{"key":"2026020203382742200_ejhfhfp066-bib-0020","first-page":"CD003566","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease","volume":"4","author":"Salpeter","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 4","key":"2026020203382742200_ejhfhfp066-bib-0021","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1097\/00005344-198608004-00022","article-title":"A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction","volume":"8","author":"Dorow","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020203382742200_ejhfhfp066-bib-0022","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/clc.4960060305","article-title":"Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease","volume":"6","author":"Fenster","year":"1983","journal-title":"Clin Cardiol"},{"key":"2026020203382742200_ejhfhfp066-bib-0023","first-page":"5","article-title":"Acute effects of oral metoprolol on ventilatory function in patients with chronic obstructive lung disease","volume":"8","author":"Sorbini","year":"1982","journal-title":"Acta Ther"},{"key":"2026020203382742200_ejhfhfp066-bib-0024","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0007-0971(78)90062-1","article-title":"The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction","volume":"72","author":"McGavin","year":"1978","journal-title":"Br J Dis Chest"},{"key":"2026020203382742200_ejhfhfp066-bib-0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00606650","article-title":"Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris","volume":"31","author":"Dorow","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"2026020203382742200_ejhfhfp066-bib-0026","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2125.1988.tb05278.x","article-title":"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction","volume":"26","author":"Macquin-Mavier","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"2026020203382742200_ejhfhfp066-bib-0027","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1152\/jappl.1983.54.5.1368","article-title":"Effect of beta-adrenergic blockade on hyperventilation and exercise tolerance in emphysema","volume":"54","author":"Butland","year":"1983","journal-title":"J Appl Physiol"},{"key":"2026020203382742200_ejhfhfp066-bib-0028","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1513\/pats.200409-045MS","article-title":"Distribution of receptor targets in the lung","volume":"1","author":"Barnes","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"2026020203382742200_ejhfhfp066-bib-0029","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00627916","article-title":"Cardioselectivity of atenolol in asthmatic patients","volume":"21","author":"Ellis","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"key":"2026020203382742200_ejhfhfp066-bib-0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00544035","article-title":"Dose\u2013response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis","volume":"27","author":"Dorow","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"2026020203382742200_ejhfhfp066-bib-0031","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2125.1984.tb02474.x","article-title":"Assessment of beta-adrenoceptor selectivity of a new beta-adrenoceptor antagonist, bisoprolol, in man","volume":"18","author":"Tattersfield","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"2026020203382742200_ejhfhfp066-bib-0032","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2710.2003.00477.x","article-title":"A comparison of the beta1-selectivity of three beta1-selective beta-blockers","volume":"28","author":"Nuttall","year":"2003","journal-title":"J Clin Pharm Ther"},{"issue":"Suppl. 5","key":"2026020203382742200_ejhfhfp066-bib-0033","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/00005344-199006165-00008","article-title":"Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study","volume":"16","author":"Dorow","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020203382742200_ejhfhfp066-bib-0034","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1164\/ajrccm.163.6.2002129","article-title":"Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease","volume":"163","author":"On","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. M","key":"2026020203382742200_ejhfhfp066-bib-0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/eurheartj\/8.suppl_M.3","article-title":"Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy","volume":"8","author":"Wellstein","year":"1987","journal-title":"Eur Heart J"},{"key":"2026020203382742200_ejhfhfp066-bib-0036","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ejheart.2007.04.006","article-title":"Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?","volume":"9","author":"Agostoni","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026020203382742200_ejhfhfp066-bib-0037","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1001\/archinte.167.22.2503","article-title":"Range and severity of symptoms over time among older adults with chronic obstructive pulmonary disease and heart failure","volume":"167","author":"Walke","year":"2007","journal-title":"Arch Intern Med"},{"key":"2026020203382742200_ejhfhfp066-bib-0038","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1067\/mhl.2001.118303","article-title":"Evaluation of 3 quality of life measurement tools in patients with chronic heart failure","volume":"30","author":"Sneed","year":"2001","journal-title":"Heart Lung"},{"key":"2026020203382742200_ejhfhfp066-bib-0039","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1071-9164(99)90030-1","article-title":"Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure","volume":"5","author":"Havranek","year":"1999","journal-title":"J Card Fail"},{"key":"2026020203382742200_ejhfhfp066-bib-0040","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1378\/chest.117.4.976","article-title":"Long-term effects of outpatient rehabilitation of COPD: a randomized trial","volume":"117","author":"Guell","year":"2000","journal-title":"Chest"},{"issue":"Suppl. B","key":"2026020203382742200_ejhfhfp066-bib-0041","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.rmed.2005.09.011","article-title":"Measuring the effects of COPD on the patient","volume":"99","author":"Jones","year":"2005","journal-title":"Respir Med"},{"key":"2026020203382742200_ejhfhfp066-bib-0042","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/thorax.56.11.880","article-title":"Health status measurement in chronic obstructive pulmonary disease","volume":"56","author":"Jones","year":"2001","journal-title":"Thorax"},{"key":"2026020203382742200_ejhfhfp066-bib-0043","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1378\/chest.130.3.647","article-title":"Effect of fluticasone propionate\/salmeterol on lung hyperinflation and exercise endurance in COPD","volume":"130","author":"O\u2019Donnell","year":"2006","journal-title":"Chest"},{"key":"2026020203382742200_ejhfhfp066-bib-0044","first-page":"681","article-title":"Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema","volume":"1","author":"Medical Research Council Working Party","year":"1981","journal-title":"Lancet"},{"key":"2026020203382742200_ejhfhfp066-bib-0045","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1183\/09031936.94.07050856","article-title":"Arterial blood gases in elderly persons with chronic obstructive pulmonary disease (COPD)","volume":"7","author":"Delclaux","year":"1994","journal-title":"Eur Respir J"},{"key":"2026020203382742200_ejhfhfp066-bib-0046","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejheart.2006.02.001","article-title":"Carvedilol reduces exercise-induced hyperventilation: a benefit in normoxia and a problem with hypoxia","volume":"8","author":"Agostoni","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026020203382742200_ejhfhfp066-bib-0047","first-page":"1048","article-title":"Effect of dipyridamole and propanolol on pulmonary diffusing capacity during rest and exercise","volume":"98","author":"Brashear","year":"1968","journal-title":"Am Rev Respir Dis"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfp066","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfp066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hfp066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hfp066","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/11\/7\/684\/66547223\/eurjhf_11_7_684.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/11\/7\/684\/66547223\/eurjhf_11_7_684.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:38:43Z","timestamp":1770021523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/11\/7\/684\/8438973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,24]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,6,24]]},"published-print":{"date-parts":[[2009,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfp066","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,7]]},"published":{"date-parts":[[2009,6,24]]}}}